Recent Updates
Recently added Catalysts
ERAS Positive Sentiment Score: 75/100

Erasca to Present at the Bank of America Securities Health Care Conference

Key Takeaway: Erasca, Inc. (Nasdaq: ERAS) is set to present at the 2026 Bank of America Securities Health Care Conference in Las Vegas on May 13, 2026. The event will feature a fireside chat followed by one-on-one investor meetings. A live audio webcast and an archived replay will be accessible on the company's website. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers, emphasizing its commitment to erasing cancer.

Market Sentiment Analysis

POSITIVE FACTORS

  • Erasca is participating in a major health care conference, raising visibility.
  • The company has a focused mission on developing therapies for RAS/MAPK-driven cancers.
  • Participation includes one-on-one meetings, facilitating potential investment.
  • Erasca's team consists of leading experts in precision oncology, enhancing credibility.

Full Press Release Details

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2026 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will participate in a fireside chat on Wednesday, May 13, 2026, at 3:00 pm Pacific Time and will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
LifeSci Advisors, LLC

Frequently Asked Questions

What is Erasca, Inc. focused on?

Erasca, Inc. specializes in therapies for RAS/MAPK pathway-driven cancers.

When is the Health Care Conference participation?

Erasca will participate on May 13, 2026, at 3:00 pm Pacific Time.

Where can I watch the Erasca event online?

The live audio webcast is available at Erasca.com/events.

How long will the archived event be available?

The archived event will be available for 30 days post-webcast.

Who co-founded Erasca, Inc.?

Erasca was co-founded by pioneers in precision oncology and RAS targeting.

Last updated: May 6, 2026